Navigation Links
Signal protein shows promise for blocking tumor promoters in skin cells

A protein with the ironic name "Srcasm" can counteract the effects of tumor-promoting molecules in skin cells, according to new research by investigators at the University of Pennsylvania School of Medicine. Using animal models, the researchers discovered that Srcasm acts like a brake in epithelial cells, preventing uncontrolled cell growth caused by a family of proteins called Src kinases. This finding, published online in the Journal of Biological Chemistry, suggests a target for future gene therapy to treat skin, head, neck, colon, and breast cancers.

Investigators have known for decades that Src kinase proteins can promote tumor formation. Src kinase activity is elevated in most skin cancers and in common carcinomas, including those of the breast and colon. At the same time, levels of the signaling molecule Srcasm are typically low in tumor cells, notes senior author John Seykora, MD, PhD, Assistant Professor of Dermatology. The current findings show that Srcasm can reduce the amount of Src kinases in cells; they have also shown that increased activity of these kinases is associated with cancerous skin lesions.

Src kinase proteins act like messengers, sending signals that control cellular growth. Found just inside the cell membrane, they conduct signals from cell surface receptors to the proteins that promote growth. Src kinases can be activated during cell division or through mutation. If these proteins are too active, they promote rapid cell growth that can spin out of control. In skin cells, Src kinases and Srcasm are involved in signaling pathways that control cell growth and differentiation.

See Saw Action
The researchers decided to test whether Srcasm could counteract the errant effects of Src kinases. They developed strains of mice with high levels of Srcasm, which had normal skin, and other strains that over-expressed the Src-kinase called Fyn, which resulted in uncontrolled cell growth with thick, scaly, hairless plaque s on the skin. These plaques, or lesions, resembled precursors of cancer. Breeding experiments with the mice indicated that high Srcasm levels counteracted the effects of Fyn.

The findings reveal that levels of Fyn and Srcasm work in a kind of see-saw ?when Srcasm production is low, dangerous amounts of Fyn can build up in cells. But when Srcasm production is increased, Fyn levels go down. "The binding of Srcasm to Fyn regulates Fyn's persistence in the cell," says Seykora. "If Srcasm is low, Fyn persists longer and sends more growth-promoting signals."

Reversing Tumors
Eventually, Srcasm might play a role in targeted gene therapies for cancers that are triggered by activated Src kinases. Such a therapy would likely use an adenovirus to carry a gene that codes for Srcasm into skin cells to increase Srcasm production, as used in some other gene therapy treatments. Initially, clinicians may try this method on oral cavity and skin cancers.

Next, the Penn researchers will determine whether Srcasm can actually reverse tumor formation in skin. Seykora's team has already prepared an adenovirus and mice with the tumor-forming Src kinases expressed in their skin. Within six months, the group expects to know whether Srcasm can decrease squamous cell carcinoma formation in skin, mentions Seykora.

Source:University of Pennsylvania School of Medicine

Related biology news :

1. Signaling protein builds bigger, better bones in mice
2. Computational Method Speeds Mapping of Cell Signaling Networks
3. Signaling for cartilage
4. New, automated tool successfully classifies and relates proteins in unprecedented way
5. New binding target for oncogenic viral protein
6. Controversial drug shown to act on brain protein to cut alcohol use
7. Timing is everything: First step in protein building revealed
8. UWs Rosetta software to unlock secrets of many human proteins
9. Researchers find how protein allows insects to detect and respond to pheromones
10. Ancient olfaction protein is shared by many bugs, offering new pest control target
11. Automatic extraction of gene/protein biological functions from biomedical text

Post Your Comments:

(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: ... to provide their customers enhanced security to access ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology: